Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Holiday Inn Amsterdam - Arena Towers

Nov 14, 2022 9:00 AM - Nov 17, 2022 5:00 PM

Hoogoorddreef 66a, 1101 BE Amsterdam, Netherlands

DIA/MEB Excellence in Pharmacovigilance: GVP Modules I to XVI

This DIA/MEB face-to-face training course is designed to provide a strong foundation in all key aspects of European Post-Marketing Safety regulatory requirements.


Organized and delivered in collaboration with the Dutch Medicines Evaluation Board (MEB), this face-to-face training course covers the major pharmacovigilance processes as outlined in GVP I to XVI. It is designed to provide a strong foundation in all key aspects of European Post-Marketing Safety regulatory requirements.
Furthermore, it includes highlights and updates on the pharmacovigilance legislation as well as the latest news on the ICH activities in pharmacovigilance.


Featured topics

This training course will take place in Amsterdam, allowing live interaction and real-time Q&A with the large panel of renowned experts onsite. We have also decided to make this course available for virtual participation (please see the links below), with some limitation regarding interaction with fellow participants and faculty members. You can register for your preferred format immediately and without concern: DIA will monitor the situation and keep all registrants informed on a regular basis.


Who should attend?

Professionals with experience in safety related activities of the drug development process and/or those with a need of a holistic overview about all PV related regulatory requirements will benefit most, such as:

  • Pharmacovigilance Officers, Managers, Specialists, Experts, or Coordinators
  • Regulatory Compliance, Quality or Safety departments Heads, Directors or Managers

Level: /Intermediate


Learning objectives

At the end of this training course, participants will be able to:

  • Understand key definitions and methods in pharmacovigilance
  • Describe the expedited and periodic ICSR reporting requirements in post-marketing
  • Understand the process of audits and inspections in pharmacovigilance
  • Understand the principles of signal management
  • Describe the components of risk management in pharmacovigilance



Program Committee

  • Wendy  Huisman, PharmD
    Wendy Huisman, PharmD Director
    Vigifit, Netherlands
  • Fakhredin Sayed Tabatabaei, MD, PhD
    Fakhredin Sayed Tabatabaei, MD, PhD Senior Assessor
    MEB, Netherlands

Digital Learning Catalog

DIA Learning: eLearning Soultions

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.